PL4021505T3 - Lek do leczenia chorób zakaźnych - Google Patents
Lek do leczenia chorób zakaźnychInfo
- Publication number
- PL4021505T3 PL4021505T3 PL20800353.3T PL20800353T PL4021505T3 PL 4021505 T3 PL4021505 T3 PL 4021505T3 PL 20800353 T PL20800353 T PL 20800353T PL 4021505 T3 PL4021505 T3 PL 4021505T3
- Authority
- PL
- Poland
- Prior art keywords
- medicament
- infectious diseases
- treating infectious
- treating
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2019127185A RU2778521C2 (ru) | 2019-08-29 | Лекарственное средство для лечения бактериальных инфекций | |
| RU2019127186A RU2778522C2 (ru) | 2019-08-29 | Лекарственное средство для лечения инфекционных заболеваний | |
| PCT/RU2020/050193 WO2021040570A1 (en) | 2019-08-29 | 2020-08-19 | Medicament and method for treating infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4021505T3 true PL4021505T3 (pl) | 2024-06-24 |
Family
ID=73040208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20800353.3T PL4021505T3 (pl) | 2019-08-29 | 2020-08-19 | Lek do leczenia chorób zakaźnych |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220213197A1 (pl) |
| EP (1) | EP4021505B1 (pl) |
| JP (2) | JP2022545178A (pl) |
| CN (1) | CN114375200A (pl) |
| BR (1) | BR112022001472A2 (pl) |
| CY (1) | CY1126747T1 (pl) |
| DK (1) | DK4021505T3 (pl) |
| ES (1) | ES2973183T3 (pl) |
| FI (1) | FI4021505T3 (pl) |
| HR (1) | HRP20240331T1 (pl) |
| HU (1) | HUE065591T2 (pl) |
| MX (1) | MX2022000536A (pl) |
| PL (1) | PL4021505T3 (pl) |
| PT (1) | PT4021505T (pl) |
| RS (1) | RS65255B1 (pl) |
| SI (1) | SI4021505T1 (pl) |
| WO (1) | WO2021040570A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117771379B (zh) * | 2023-10-25 | 2024-08-30 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2197266C1 (ru) * | 2001-06-01 | 2003-01-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта |
| RU2205025C1 (ru) * | 2001-12-26 | 2003-05-27 | Гольдберг Евгений Данилович | Способ коррекции иммунного ответа и лекарственное средство |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| RU2363470C1 (ru) | 2007-12-26 | 2009-08-10 | Государственное образовательное учреждение высшего профессионального образования Самарский государственный медицинский университет | Способ преодоления лекарственной устойчивости бактерий и грибов |
| JP2013532181A (ja) * | 2010-07-15 | 2013-08-15 | イリイチ・エプシテイン オレグ | 組み合わせ医薬組成物及び胃腸管の機能的な疾患又は状態を治療する方法 |
| EP2593477A2 (en) * | 2010-07-15 | 2013-05-22 | Oleg Iliich Epshtein | Pharmaceutical compositions and methods of treatment |
| RU2521392C2 (ru) * | 2010-08-06 | 2014-06-27 | Олег Ильич Эпштейн | Комплексное лекарственное средство для лечения вирусных заболеваний и способ лечения вирусных заболеваний |
| RU2500422C2 (ru) | 2010-08-06 | 2013-12-10 | Олег Ильич Эпштейн | Комплексное лекарственное средство для лечения вирусных инфекций и способ лечения вирусных инфекций |
| WO2012017328A2 (en) * | 2010-08-06 | 2012-02-09 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases |
| RU2655808C2 (ru) | 2016-10-11 | 2018-05-29 | Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") | Фармацевтическая комбинированная композиция для местного и наружного применения на основе бактериолитического и протеолитического комплекса ферментов |
-
2020
- 2020-08-19 HR HRP20240331TT patent/HRP20240331T1/hr unknown
- 2020-08-19 JP JP2022506768A patent/JP2022545178A/ja not_active Withdrawn
- 2020-08-19 MX MX2022000536A patent/MX2022000536A/es unknown
- 2020-08-19 FI FIEP20800353.3T patent/FI4021505T3/fi active
- 2020-08-19 DK DK20800353.3T patent/DK4021505T3/da active
- 2020-08-19 SI SI202030365T patent/SI4021505T1/sl unknown
- 2020-08-19 EP EP20800353.3A patent/EP4021505B1/en active Active
- 2020-08-19 WO PCT/RU2020/050193 patent/WO2021040570A1/en not_active Ceased
- 2020-08-19 BR BR112022001472A patent/BR112022001472A2/pt unknown
- 2020-08-19 HU HUE20800353A patent/HUE065591T2/hu unknown
- 2020-08-19 PT PT208003533T patent/PT4021505T/pt unknown
- 2020-08-19 RS RS20240275A patent/RS65255B1/sr unknown
- 2020-08-19 ES ES20800353T patent/ES2973183T3/es active Active
- 2020-08-19 PL PL20800353.3T patent/PL4021505T3/pl unknown
- 2020-08-19 US US17/608,270 patent/US20220213197A1/en active Pending
- 2020-08-19 CN CN202080060725.3A patent/CN114375200A/zh active Pending
-
2024
- 2024-03-12 CY CY20241100191T patent/CY1126747T1/el unknown
- 2024-08-01 JP JP2024125562A patent/JP2024156824A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20240331T1 (hr) | 2024-06-07 |
| JP2024156824A (ja) | 2024-11-06 |
| JP2022545178A (ja) | 2022-10-26 |
| MX2022000536A (es) | 2022-02-10 |
| CN114375200A (zh) | 2022-04-19 |
| WO2021040570A1 (en) | 2021-03-04 |
| EP4021505B1 (en) | 2023-12-13 |
| PT4021505T (pt) | 2024-03-11 |
| SI4021505T1 (sl) | 2024-03-29 |
| ES2973183T3 (es) | 2024-06-18 |
| RS65255B1 (sr) | 2024-03-29 |
| US20220213197A1 (en) | 2022-07-07 |
| HUE065591T2 (hu) | 2024-06-28 |
| BR112022001472A2 (pt) | 2022-03-22 |
| DK4021505T3 (da) | 2024-02-12 |
| CY1126747T1 (el) | 2026-02-25 |
| FI4021505T3 (fi) | 2024-03-01 |
| EP4021505A1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288958A (en) | Exosomes for the treatment of diseases | |
| IL277190A (en) | Methods of treating HPV-related diseases | |
| IL277333A (en) | Methods for treating eye diseases | |
| CA189015S (en) | Medical treatment cart | |
| SG11202012339WA (en) | Co-receptor systems for treating infectious diseases | |
| IL279078A (en) | Combination therapy for the treatment of hepatitis B viral infection | |
| GB201916279D0 (en) | Tobacco treatment | |
| GB201908885D0 (en) | Therapeutic compounds | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| PT3619204T (pt) | Compostos para o tratamento de doenças respiratórias | |
| PL4021505T3 (pl) | Lek do leczenia chorób zakaźnych | |
| GB201908453D0 (en) | Compounds for treating respiratory disease | |
| GB201914296D0 (en) | Treatment | |
| GB201912365D0 (en) | Treatment | |
| GB201817469D0 (en) | Gene therapy for retinal disease | |
| IL286680A (en) | A drug to treat cancer | |
| GB201911728D0 (en) | Bacterial composistions for the treatment of disease | |
| GB201902579D0 (en) | Treatment | |
| HK40063671A (en) | Exosomes for disease treatment | |
| GB201917691D0 (en) | Compounds for treating respiratory disease | |
| GB201908451D0 (en) | Compounds for treating respiratory disease | |
| HK40038400A (en) | Treatment of infectious disease | |
| GB201903547D0 (en) | Treatment for autoimmune diseases | |
| HK40058903A (en) | Therapeutic methods for treating hepatitis b | |
| GB201912760D0 (en) | Treatment |